FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS
Biogen, 29 Apr 2015
Accessed on 12 May 2015 from http://biogen.newshq.businesswire.com/press-release/corporate/fda-accepts-biologics-license-application-zinbryta-daclizumab-high-yield-pro.